These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 12910520

  • 1. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM.
    Cancer; 2003 Aug 15; 98(4):758-64. PubMed ID: 12910520
    [Abstract] [Full Text] [Related]

  • 2. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 15; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 3. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS.
    Hum Pathol; 2005 Mar 15; 36(3):242-9. PubMed ID: 15791568
    [Abstract] [Full Text] [Related]

  • 4. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.
    Reprod Sci; 2008 Sep 15; 15(7):673-7. PubMed ID: 18492696
    [Abstract] [Full Text] [Related]

  • 5. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.
    Cancer; 2006 May 01; 106(9):2005-11. PubMed ID: 16565971
    [Abstract] [Full Text] [Related]

  • 6. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 7. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.
    J Cutan Pathol; 2006 Apr 01; 33(4):280-5. PubMed ID: 16630177
    [Abstract] [Full Text] [Related]

  • 8. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.
    Anticancer Drugs; 2006 Jul 01; 17(6):649-55. PubMed ID: 16917210
    [Abstract] [Full Text] [Related]

  • 9. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R.
    Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA.
    J Neurooncol; 2006 Jan 01; 76(2):105-9. PubMed ID: 16205964
    [Abstract] [Full Text] [Related]

  • 11. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG.
    Am J Surg Pathol; 2005 Aug 01; 29(8):1034-41. PubMed ID: 16006797
    [Abstract] [Full Text] [Related]

  • 12. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 01; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 13. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK.
    Pathol Res Pract; 2007 Jan 01; 203(3):127-34. PubMed ID: 17298867
    [Abstract] [Full Text] [Related]

  • 14. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
    Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S, Israel Glivec in Solid Tumors Study Group.
    Endocr Relat Cancer; 2006 Jun 01; 13(2):535-40. PubMed ID: 16728580
    [Abstract] [Full Text] [Related]

  • 15. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.
    Cancer; 2005 May 15; 103(10):2128-31. PubMed ID: 15812822
    [Abstract] [Full Text] [Related]

  • 16. [New oncological treatment principle with imatinib].
    Kuenen BC, Pinedo HM.
    Ned Tijdschr Geneeskd; 2003 Oct 18; 147(42):2044-5. PubMed ID: 14606348
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM.
    Gynecol Oncol; 2012 Jun 18; 125(3):640-5. PubMed ID: 22387451
    [Abstract] [Full Text] [Related]

  • 18. [Imatinib--a new perspective in the treatment of tumors].
    Klener P, Klamová H.
    Cas Lek Cesk; 2004 Jun 18; 143(9):579-80, 582-3. PubMed ID: 15532894
    [Abstract] [Full Text] [Related]

  • 19. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
    Fiorentini G, Rossi S, Lanzanova G, Biancalani M, Palomba A, Bernardeschi P, Dentico P, De Giorgi U.
    J Exp Clin Cancer Res; 2003 Dec 18; 22(4 Suppl):17-20. PubMed ID: 16767900
    [Abstract] [Full Text] [Related]

  • 20. Imatinib: a targeted clinical drug development.
    Capdeville R, Silberman S.
    Semin Hematol; 2003 Apr 18; 40(2 Suppl 2):15-20. PubMed ID: 12783370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.